

CLAIMS

What is claimed is:

1. A method of treating a disease or condition wherein migration or
5 proliferation of retinal pigment epithelium or glial cells causes or contributes to
the cause of said disease or condition, comprising administering a
therapeutically effective amount of memantine to the patient suffering from said
disease or condition.
2. The method of claim 1 wherein said disease or condition is not
10 proliferative vitreoretinopathy.
3. The method of claim 1 wherein said disease or condition is selected
from the group consisting of non-exudative age related macular degeneration,
exudative age related macular degeneration, choroidal neovascularization, acute
macular neuroretinopathy, cystoid macular edema, diabetic macular edema,
15 Behcet's disease, diabetic retinopathy, retinal arterial occlusive disease, central
retinal vein occlusion, uveitic retinal disease, retinal detachment, trauma,
conditions caused by laser treatment, conditions caused by photodynamic
therapy, photocoagulation, radiation retinopathy, epiretinal membranes,
proliferative diabetic retinopathy, branch retinal vein occlusion, anterior
20 ischemic optic neuropathy, non-retinopathy diabetic retinal dysfunction, and
retinitis pigmentosa.
4. The method of claim 1 wherein said disease or condition is selected
from the group consisting of non-exudative age related macular degeneration,
exudative age related macular degeneration, choroidal neovascularization, acute
25 macular neuroretinopathy, cystoid macular edema, diabetic macular edema,
Behcet's disease, diabetic retinopathy, retinal arterial occlusive disease, central
retinal vein occlusion, uveitic retinal disease, retinal detachment, trauma,
conditions caused by laser treatment, conditions caused by photodynamic
therapy, photocoagulation, radiation retinopathy, epiretinal membranes, branch
30 retinal vein occlusion, anterior ischemic optic neuropathy, non-retinopathy
diabetic retinal dysfunction, and retinitis pigmentosa.

5. The method of claim 1 wherein said disease or condition is selected from the group consisting of non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, acute macular neuroretinopathy, cystoid macular edema, diabetic macular edema,
5 Behcet's disease, diabetic retinopathy, retinal arterial occlusive disease, central retinal vein occlusion, uveitic retinal disease, retinal detachment, trauma, conditions caused by laser treatment, conditions caused by photodynamic therapy, photocoagulation, radiation retinopathy, epiretinal membranes, proliferative diabetic retinopathy, branch retinal vein occlusion, anterior
10 ischemic optic neuropathy, non-retinopathy diabetic retinal dysfunction, and retinitis pigmentosa.
6. The method of claim 1 wherein said disease is proliferative diabetic retinopathy.
7. The method of claim 1 wherein the memantine is administered orally.
- 15 8. The method of claim 1 wherein the memantine is administered topically.
9. The method of claim 1 wherein the memantine is administered to the eye or the surrounding tissue via implant or injection.
10. The method of claim 1 wherein the memantine is administered chronically.
- 20 11. A method of treating a disease or condition, comprising administering a therapeutically effective amount of memantine to a mammal suffering from said disease or condition, wherein said disease or condition is selected from the group consisting of non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, acute macular
25 neuroretinopathy, cystoid macular edema, diabetic macular edema, Behcet's disease, diabetic retinopathy, retinal arterial occlusive disease, central retinal vein occlusion, uveitic retinal disease, retinal detachment, trauma, conditions caused by laser treatment, conditions caused by photodynamic therapy, photocoagulation, radiation retinopathy, epiretinal membranes, proliferative
30 diabetic retinopathy, branch retinal vein occlusion, anterior ischemic optic neuropathy, non-retinopathy diabetic retinal dysfunction, and retinitis pigmentosa.

12. The method of claim 11 wherein said disease or condition is selected from the group consisting of non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, acute macular neuroretinopathy, cystoid macular edema, diabetic macular edema,
- 5 Behcet's disease, diabetic retinopathy, retinal arterial occlusive disease, central retinal vein occlusion, uveitic retinal disease, retinal detachment, trauma, conditions caused by laser treatment, conditions caused by photodynamic therapy, photocoagulation, radiation retinopathy, epiretinal membranes, branch retinal vein occlusion, anterior ischemic optic neuropathy, non-retinopathy
- 10 diabetic retinal dysfunction, and retinitis pigmentosa.
13. The method of claim 11 wherein said disease or condition is selected from the group consisting of non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, acute macular neuroretinopathy, cystoid macular edema, diabetic macular edema,
- 15 Behcet's disease, diabetic retinopathy, retinal arterial occlusive disease, central retinal vein occlusion, uveitic retinal disease, retinal detachment, trauma, conditions caused by laser treatment, conditions caused by photodynamic therapy, photocoagulation, radiation retinopathy, epiretinal membranes, proliferative diabetic retinopathy, branch retinal vein occlusion, anterior
- 20 ischemic optic neuropathy, non-retinopathy diabetic retinal dysfunction, and retinitis pigmentosa.
14. The method of claim 11 wherein said disease is proliferative diabetic retinopathy.
15. The method of claim 11 wherein the memantine is administered orally.
- 25 16. The method of claim 11 wherein the memantine is administered topically.
17. The method of claim 11 wherein the memantine is administered to the eye or the surrounding tissue via implant or injection.
18. The method of claim 11 wherein the memantine is administered
- 30 chronically.